EK1

EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats[1].

Product Specifications

UNSPSC

12352209

Target

SARS-CoV

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N

Molecular Formula

C196H317N43O64S

Molecular Weight

4331.93

References & Citations

[1]Monteiro A, et al. Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond. Curr HIV Res. 2021;19 (6) :465-475.